XGX Pharma ApS Financials, key figures and credit report
Gross profit 32 338.4 kDKK FY 2025 +101.7% vs 2024
EBIT 21 199.2 kDKK FY 2025 +224.3% vs 2024
Net debt 5 119.0 kDKK FY 2025 -19.1% vs 2024
Quick ratio 1.4 FY 2025 +0.1 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | 14 515.29 | 2 917.68 | 8 100.82 | 16 033.79 | 32 338.38 |
| Employee benefit expenses | -5 008.32 | -4 419.96 | -5 200.47 | -7 262.73 | -8 149.18 |
| Total depreciation | - 434.13 | - 787.67 | -1 424.09 | -2 234.34 | -2 990.05 |
| EBIT | 9 072.84 | -2 289.95 | 1 476.26 | 6 536.73 | 21 199.15 |
| Other financial income | 5.79 | 0.58 | 7.70 | 34.53 | |
| Other financial expenses | - 407.80 | - 484.94 | - 786.35 | - 873.21 | - 870.31 |
| Net income from associates (fin.) | 143.13 | 87.85 | -82.30 | -50.52 | 139.82 |
| Pre-tax profit | 8 931.62 | -2 681.26 | 623.69 | 5 673.08 | 20 508.85 |
| Income taxes | -1 683.12 | 838.70 | - 162.79 | -1 219.65 | -4 434.73 |
| Net earnings | 7 248.51 | -1 842.55 | 460.89 | 4 453.43 | 16 074.12 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Development expenditure | 11 329.47 | 14 835.84 | 16 329.09 | 17 499.10 | 18 371.09 |
| Intangible rights | 649.94 | 668.50 | 769.22 | ||
| Intangible assets total | 11 329.47 | 14 835.84 | 16 979.03 | 18 167.60 | 19 140.31 |
| Machinery and equipment | 527.16 | 365.02 | 170.63 | 22.74 | 13.84 |
| Tangible assets total | 527.16 | 365.02 | 170.63 | 22.74 | 13.84 |
| Holdings in group member companies | 143.13 | 230.98 | 148.69 | 105.50 | 245.32 |
| Investments total | 334.61 | 437.94 | 381.67 | 341.70 | 486.09 |
| Long term receivables total | |||||
| Finished products/goods | 2 395.16 | 3 044.19 | 2 679.14 | 3 266.20 | 6 284.51 |
| Inventories total | 2 395.16 | 3 044.19 | 2 679.14 | 3 266.20 | 6 284.51 |
| Current trade debtors | 2 589.39 | 3 968.11 | 2 932.76 | 13 053.82 | 10 682.42 |
| Current amounts owed by group member comp. | 250.00 | 164.70 | 288.25 | 559.30 | |
| Current other receivables | 3 627.18 | 4 508.67 | 6 144.47 | 3 736.89 | 17 948.43 |
| Current deferred tax assets | 204.44 | 479.90 | 148.80 | 129.00 | |
| Short term receivables total | 6 671.02 | 8 956.68 | 9 390.73 | 17 207.96 | 29 190.14 |
| Balance sheet total (assets) | 21 257.41 | 27 639.68 | 29 601.20 | 39 006.20 | 55 114.89 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 132.98 | 400.00 | 400.00 | 400.00 | 400.00 |
| Shares repurchased | 4 000.00 | ||||
| Other reserves | 9 039.08 | 11 819.74 | 12 885.38 | 13 747.46 | 14 567.43 |
| Retained earnings | -3 251.70 | 3 421.55 | 513.36 | -3 887.83 | - 254.37 |
| Profit of the financial year | 7 248.51 | -1 842.55 | 460.89 | 4 453.43 | 16 074.12 |
| Shareholders equity total | 13 168.87 | 13 798.74 | 14 259.63 | 18 713.06 | 30 787.18 |
| Provisions | 2 508.61 | 1 669.91 | 1 832.71 | 3 052.36 | 4 016.38 |
| Non-current loans from credit institutions | 1 947.94 | 7 648.62 | 5 873.36 | 3 952.76 | |
| Non-current liabilities total | 1 947.94 | 7 648.62 | 5 873.36 | 3 952.76 | |
| Current loans from credit institutions | 0.06 | 1 775.26 | 2 370.73 | ||
| Advances received | 752.55 | ||||
| Current trade creditors | 2 343.63 | 3 309.29 | 4 644.41 | 4 790.24 | |
| Current owed to participating | 1.93 | ||||
| Current owed to group member | 55.81 | 5 119.01 | |||
| Short-term deferred tax liabilities | 611.60 | 3 489.10 | |||
| Other non-interest bearing current liabilities | 3 020.33 | 1 370.42 | 2 550.96 | 6 270.95 | 6 912.98 |
| Current liabilities total | 3 631.99 | 4 522.41 | 7 635.51 | 13 288.02 | 20 311.32 |
| Balance sheet total (liabilities) | 21 257.41 | 27 639.68 | 29 601.20 | 39 006.20 | 55 114.89 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated